We are live on ! Find out more
BIOT

Biotech Acquisition Company Class A Ordinary Shares
BIOT

Delisted

BIOT was delisted on the 2nd of February, 2023.

Back to rankings

68 hedge funds and large institutions have $226M invested in Biotech Acquisition Company Class A Ordinary Shares in 2022 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 8 increasing their positions, 11 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more capital invested

Capital invested by funds: $226M → $226M (+$279K)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

1% less funds holding

Funds holding: 69 → 68 (-1)

17% less first-time investments, than exits

New positions opened: 5 | Existing positions closed: 6

27% less repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 11

Holders
68
Holders Change
-1
Holders Change %
-1.45%
% of All Funds
1.09%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
5
Increased
8
Reduced
11
Closed
6
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
AC
Aristeia Capital
Connecticut
+$3.75M
2
WRBC
W.R. Berkley Corp
Connecticut
+$1.99M
3
WA
Whitebox Advisors
Minnesota
+$1.15M
4
CS
Credit Suisse
Switzerland
+$793K
5
BI
Bulldog Investors
New Jersey
+$557K

Top Sellers

Rank Fund Capital Flow
1
CM
Cohanzick Management
New York
-$7.93M
2
PC
Periscope Capital
Ontario, Canada
-$2.02M
3
MSU
Mizuho Securities USA
New York
-$1.95M
4
Citadel Advisors
Citadel Advisors
Florida
-$1.44M
5
JP Morgan Chase
JP Morgan Chase
New York
-$995K
Name Holding Trade Value Shares
Change 		Change in
Stake
GCL
1
Glazer Capital LLC
New York
$23.1M -$10.9K -1,090 -0%
AC
2
Aristeia Capital
Connecticut
$15.4M +$3.75M +375,000 +33%
Hudson Bay Capital Management
3
Hudson Bay Capital Management
Connecticut
$12.7M – – –
Marshall Wace
4
Marshall Wace
United Kingdom
$10.2M – – –
SCM
5
Saba Capital Management
New York
$9.75M – – –
D.E. Shaw & Co
6
D.E. Shaw & Co
New York
$9.38M – – –
CCP
7
Corbin Capital Partners
New York
$9.37M – – –
RA
8
RiverPark Advisors
New York
$8.07M – – –
Millennium Management
9
Millennium Management
New York
$7.14M – – –
HSBC Holdings
10
HSBC Holdings
United Kingdom
$6.45M – – –
FTCM
11
Fir Tree Capital Management
New York
$6.42M -$109K -10,931 -2%
PAMP
12
Polar Asset Management Partners
Ontario, Canada
$6.23M +$501K +50,000 +9%
MI
13
MMCAP International
Cayman Islands
$6.05M – – –
AWG
14
Alpha Wave Global
New York
$5.38M – – –
WCMNY
15
Westchester Capital Management (New York)
New York
$5.26M – – –
WRBC
16
W.R. Berkley Corp
Connecticut
$4.92M +$1.99M +199,032 +69%
RCM
17
Radcliffe Capital Management
Pennsylvania
$4.61M – – –
DKCM
18
Davidson Kempner Capital Management
New York
$4.54M – – –
Nomura Holdings
19
Nomura Holdings
Japan
$4.04M – – –
MF
20
Magnetar Financial
Illinois
$3.84M – – –
State of Wisconsin Investment Board
21
State of Wisconsin Investment Board
Wisconsin
$3.64M – – –
RL
22
RPO LLC
Connecticut
$3.63M -$200K -20,012 -5%
AA
23
AQR Arbitrage
Connecticut
$3.55M – – –
SC
24
Sculptor Capital
New York
$3.04M – – –
ACA
25
Arena Capital Advisors
California
$3.03M – – –
1
2 3

BIOT Hedge Fund Activity: Q4 2022 in Review

68 of the 6,222 institutional investors tracked by Wall St. Rank reported a position in Biotech Acquisition Company Class A Ordinary Shares (BIOT) for Q4 2022, worth a combined $226M — up 0.12% from $226M a quarter earlier.

Sellers outnumbered buyers: 6 funds closed out of BIOT and 5 opened new positions — a net loss of 1 holder — while 11 trimmed existing stakes and 8 added.

The largest buyer was Aristeia Capital, adding an estimated $3.75M. The largest seller was Cohanzick Management, exiting entirely with an estimated $7.93M sold.

  • 68 institutional investors held Biotech Acquisition Company Class A Ordinary Shares (BIOT) as of Q4 2022, down from 69 in Q3 2022.
  • Funds reported $226M of Biotech Acquisition Company Class A Ordinary Shares stock for Q4 2022, up 0.12% quarter-over-quarter.
  • 5 funds opened new Biotech Acquisition Company Class A Ordinary Shares positions in Q4 2022 and 6 closed out, a net change of -1 holder.
  • The largest Biotech Acquisition Company Class A Ordinary Shares buyer in Q4 2022 was Aristeia Capital, an estimated $3.75M added.
  • The largest Biotech Acquisition Company Class A Ordinary Shares seller in Q4 2022 was Cohanzick Management, an estimated $7.93M sold.

Based on aggregated 13F filings for Q4 2022.